Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer a secondary analysis of a randomized clinical trial

JAMA Oncology

Volumn 4, Issue 4, 2018, Pages 545-553

  Sestak, Ivana ^a   Buus, Richard ^b,c   Cuzick, Jack ^a   Dubsky, Peter ^d,e   Kronenwett, Ralf ^f   Denkert, Carsten ^g   Ferree, Sean ^h   Sgroi, Dennis ⁱ   Schnabel, Catherine ^j   Baehner, Frederick L ^k   Mallon, Elizabeth ^l   Dowsett, Mitch ^b,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Ralph Lauren Centre for Breast Cancer Research   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Klinik St Anna   (Switzerland)

^f Sividon Diagnostics GmbH   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h NANOSTRING TECHNOLOGIES   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j Biotheranostics   (United States)

^k Genomic Health   (United States)

^l UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; PHARMACOLOGICAL BIOMARKER; TRANSCRIPTOME; TUMOR MARKER;

4 MARKER IMMUNOHISTOCHEMICAL SCORE; ADULT; AGE; AGED; ARTICLE; BREAST CANCER INDEX; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SIZE; CLINICAL TREATMENT SCORE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; ENDOPREDICT; ERBB2 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; ONCOTYPE DX RECURRENCE SCORE; PAM50-BASED PROSIGNA RISK OF RECURRENCE; PERFORMANCE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SCORING SYSTEM; SECONDARY ANALYSIS; TREATMENT DURATION; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PREVENTION AND CONTROL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANASTROZOLE; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, PHARMACOLOGICAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TAMOXIFEN; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 85046827104     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.5524     Document Type: Article

References (28)

1. Massagué J. Sorting out breast-cancer gene signatures. N Engl J Med. 2007;356(3):294-297.
2. Harris LN, Ismaila N, McShane LM, et al; American Society of Clinical Oncology. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34 (10):1134-1150.
3. Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284-298.
4. Coates AS, Winer EP, Goldhirsch A, et al; Panel Members. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-1546.
5. Senkus E, Kyriakides S, Ohno S, et al; ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v8-v30.
6. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273-4278.
7. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783-2790.
8. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor–positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14(11):1067-1076.
9. Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. 2016;108(11). doi:10.1093/jnci/djw149
10. Dubsky P, Brase JC, Jakesz R, et al; Austrian Breast and Colorectal Cancer Study Group (ABCSG). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients. Br J Cancer. 2013;109(12):2959-2964.
11. Filipits M, Nielsen TO, Rudas M, et al; Austrian Breast and Colorectal Cancer Study Group. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res. 2014;20(5):1298-1305.
12. Cuzick J, Sestak I, Baum M, et al; ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-1141.
13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-2826.
14. Tang G, Cuzick J, Costantino JP, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor–positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol. 2011;29(33):4365-4372.
15. Jerevall PL, Ma XJ, Li H, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer. 2011;104(11):1762-1769.
16. Ma XJ, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res. 2008;14(9): 2601-2608.
17. Zhang Y, Schnabel CA, Schroeder BE, et al. Breast cancer index identifies early-stage estrogen receptor–positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res. 2013;19(15):4196-4205.
18. Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 2015;33(8):916-922.
19. Filipits M, Rudas M, Jakesz R, et al; EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-6020.
20. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.
21. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360(8):790-800.
22. Sgroi DC, Carney E, Zarrella E, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013;105(14):1036-1042.
23. Gnant M, Filipits M, Mlineritsch B, et al. Abstract P2-10-02: clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): an ABCSG study. Cancer Res. 2012;72:P2-P10. doi:10.1158/0008 -5472.SABCS12-P2-10-02
24. Wolmark N, Mamounas EP, Baehner FL, et al. Prognostic impact of the combination of recurrence score and quantitative estrogen receptor expression (ESR1) on predicting late distant recurrence risk in estrogen receptor-positive breast cancer after 5 years of tamoxifen: results from NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. J Clin Oncol. 2016;34 (20):2350-2358.
25. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209-219.
26. Mamounas E, Bandos H, Lembersky BC, et al. Abstract S1-05: a randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): results from NRG Oncology/NSABP B-42. Cancer Res. 2017;77:S1-S05. doi:10.1158/1538-7445 .SABCS16-S1-05
27. Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer: results of the IDEAL trial (BOOG 2006-05) [published online January 1, 2018]. J Natl Cancer Inst. doi:10.1093/jnci /djx134
28. Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017;18(11):1502-1511.